Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin

American Journal of Health-System Pharmacy

Volumn 63, Issue 7, 2006, Pages 653-656

  Washington, Carla ^a   Hou, Eddie ^b   Hughes, Nicki ^c   Berner, Bret ^b  

^a Clinical Pharmacokinetics ^*

^b Pharmacokinetics Depomed Inc   (United States)

^c Biovail Contract Research   (Canada)

Author keywords

Blood levels; Ciprofloxacin hydrochloride; Drug interactions; Drugs, availability; Excretion; Gastrointestinal drugs; Omeprazole; Pharmacokinetics; Quinolones; Sustained action medications; Urine levels

Indexed keywords

CIPROFLOXACIN; OMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG INHIBITION; DRUG URINE LEVEL; EXTENDED RELEASE FORMULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION;

EID: 33645502189     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050355     Document Type: Article

References (11)

1. Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996; 51:1019-74.
2. Vance-Bryan K, Guay DR, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet. 1990; 19:434-61.
3. Harder S, Fuhr U, Beermann D et al. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br J Clin Pharmacol. 1990; 30:35-9.
4. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet. 1991; 21:195-212.
5. Oosterhuis B, Jonkman JH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion. 1989; 44(suppl 1):9-17.
6. Stuht H, Lode H, Koeppe P et al. Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother. 1995; 39:1045-9.
7. Cipro XR package insert. West Haven, CT: Bayer; 2004 Oct.
8. Prilosec package insert. Wilmington, DE: AstraZeneca LP; 2003 Dec.
9. Fourcroy JL, Berner B, Chiang YK et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother. 2005; 49:4137-43.
10. Washington CB, Hou E, Campanella C et al. Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers. J Clin Pharmacol. 2005; 45:1236-44.
11. Data on file. Study 81-0029. Menlo Park, CA: Depomed, Inc., 2004.